Crescendo Biologics (Formerly Translocus)
Biopharmaceutical developing potent, highly differentiated Humabody® VH therapeutics in Oncology..
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | €28.9m Valuation: €285m | Late VC | |
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (26 %) | 316 % | (38 %) | 24 % | (15 %) | (57 %) | 205 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (394 %) | (20 %) | (167 %) | (122 %) | (139 %) | (900 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (526 %) | (24 %) | (125 %) | (119 %) | (114 %) | (636 %) | (315 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 92 % | 86 % | 107 % | 86 % | - | - | - |
Source: Company filings or news article
Related Content
Crescendo Biologics is a biopharmaceutical company that operates in the healthcare sector, specifically in the development of innovative cancer treatments. The company's primary focus is on the engineering of immunoglobulin technology, a type of protein used by the immune system to neutralize harmful substances. This technology has recently been recognized by the European Patent Office, marking a significant milestone for the company.
Crescendo Biologics serves a market of healthcare providers and patients, particularly those affected by solid tumours. The company is currently expanding its Phase 1b trial of CB307, a treatment for PSMA+ solid tumours, having secured $32M in funding. This demonstrates the company's commitment to advancing its research and development efforts.
In addition to its own research, Crescendo Biologics also collaborates with other companies in the healthcare sector. Notably, it has partnered with BioNTech to develop multi-specific precision immunotherapies, which are treatments designed to boost the body's immune response to cancer.
The company's business model revolves around the development and commercialization of its proprietary clinical candidates. These are potential treatments that the company has developed and is testing. Once these treatments have been approved, Crescendo Biologics can then sell them to healthcare providers, generating revenue.
In summary, Crescendo Biologics is a pioneering biopharmaceutical company that develops innovative cancer treatments. It operates in the healthcare market, serving patients and healthcare providers, and generates revenue through the sale of its proprietary treatments.
Keywords: Biopharmaceutical, Cancer Treatments, Immunoglobulin Technology, Healthcare Providers, Solid Tumours, Clinical Trials, Research and Development, Collaboration, Proprietary Clinical Candidates, Revenue Generation.